To assess the efficacy and safety of AVT04, a biosimilar to ustekinumab, in patients with plaque psoriasis, specifically distinguishing between ustekinumab-naïve and switched patients.
Key Findings:
54.5% of ustekinumab-naïve patients achieved complete remission with AVT04.
37.5% of bio-experienced patients achieved complete remission.
Switching from reference ustekinumab to AVT04 was effective and safe.
Interpretation:
The study supports the efficacy and safety of AVT04 in managing plaque psoriasis, highlighting its potential as a viable alternative to reference ustekinumab in clinical practice.
Limitations:
The study's retrospective design may introduce biases that could affect the reliability of the findings.
Limited generalizability due to being conducted at a single center, which may not represent broader patient populations.
Conclusion:
AVT04 shows sustained clinical efficacy in managing plaque psoriasis, offering a cost-saving alternative for healthcare systems while significantly improving patient access to biologic therapies.
by Edoardo Mortato, Marina Talamonti, Lorenzo Savastano, Lorenzo Marcelli, Lorenzo Tofani, Valerio Gneo, Domenico Marrapodi, Maria Rosa Ingrosso, Luca Bianchi, Marco Galluzzo
